One case study of a patient with severe immune hepatotoxicity due to pembrolizumab and a resumption of immunotherapy:sharing and inspiration
A 65-year-old male patient was diagnosed with malignant tumor in right lung complicated with lymph node metastasis in lung hilum and abdomen,bone metastasis and secondary malignant tumor of adrenal gland.In March 2021,two cycles of immunochemotherapy were dosed in the regi-men of pembrolizumab(200 mg),pemetrexed disodium for injection(800 mg)and carboplatin injection(500 mg).Since liver function manifested as Grade 4 immune hepatotoxicity,pembrolizumab was terminated and liver function gradually normalized after dosing of glucocorticoid and hepatoprotective drugs.In May 2022,three cycles of immunochemotherapy were offered in the regimen of pembrolizumab(200 mg)and pemetrexed disodium for injection(800 mg).Liver function manifested as Grade 2 immune hepatotoxicity.After dosing of glucocorticoid and hepatoprotective drugs,liver function gradually normalized.
Pembrolizumabimmune hepatotoxicityadverse drug reactionretreatment
NETL
NSTL
万方数据
